Alexis Peedin

Dr. Alexis Peedin

orcid

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 January 2022 in Bone Marrow Transplantation
Verified
Journal Article
Closed access
PDF file
BFBrittany File
Brittany File
YHYanping Huang
Yanping Huang
APAlexis Peedin
Alexis Peedin
UGUsama Gergis
Usama Gergis

27 December 2019 in BMC Anesthesiology
Verified
Journal Article
Open access
PDF file
JHJustin Herman
Justin Herman
BPBrian Park
Brian Park
BABharat Awsare
Bharat Awsare
FWFrances West
Frances West
DCDenine Crittendon
Denine Crittendon
MBMichael Baram
Michael Baram
Point-of-care (POC) hemoglobin testing has the potential to revolutionize massive transfusion strategies. No prior studies have compared POC and central laboratory testing of hemoglobin in patients undergoing massive transfusions. We retrospectively compared the results of our point-of-care hemoglobin test (EPOC®) to our core laboratory complete blood count (CBC) hemoglobin test (Sysmex XE-5000™) in patients undergoing massive transfusion protocols (MTP) for hemorrhage. One hundred seventy paired samples from 90 patients for whom MTP was activated were collected at a single, tertiary care hospital between 10/2011 and 10/2017. Patients had both an EPOC® and CBC hemoglobin performed within 30 min of each other during the MTP. We assessed the accuracy of EPOC® hemoglobin testing using two variables: interchangeability and clinically significant differences from the CBC. The Clinical Laboratory Improvement Amendments (CLIA) proficiency testing criteria defined interchangeability for measurements. Clinically significant differences between the tests were defined by an expert panel. We examined whether these relationships changed as a function of the hemoglobin measured by the EPOC® and specific patient characteristics. Fifty one percent (86 of 170) of paired samples’ hemoglobin results had an absolute difference of ≤7 and 73% (124 of 170) fell within ±1 g/dL of each other. The mean difference between EPOC® and CBC hemoglobin had a bias of − 0.268 g/dL (p = 0.002). When the EPOC® hemoglobin was < 7 g/dL, 30% of the hemoglobin values were within ±7, and 57% were within ±1 g/dL. When the measured EPOC® hemoglobin was ≥7 g/dL, 55% of the EPOC® and CBC hemoglobin values were within ±7, and 76% were within ±1 g/dL. EPOC® and CBC hemoglobin values that were within ±1 g/dL varied by patient population: 77% for cardiac surgery, 58% for general surgery, and 72% for non-surgical patients. The EPOC® device had minor negative bias, was not interchangeable with the CBC hemoglobin, and was less reliable when the EPOC® value was < 7 g/dL. Clinicians must consider speed versus accuracy, and should check a CBC within 30 min as confirmation when the EPOC® hemoglobin is < 7 g/dL until further prospective trials are performed in this population.

1 December 2021 in Clinics In Laboratory Medicine
Verified
Journal Article
Closed access
APAlexis Peedin
Alexis Peedin

1 August 2024 in Blood Advances
Verified
Journal Article
Open access
PDF file
DGDolores Grosso
Dolores Grosso
JWJohn L. Wagner
John L. Wagner
AOAllyson O’cOnnor
Allyson O’cOnnor
KKKaitlyn Keck
Kaitlyn Keck
YHYanping Huang
Yanping Huang
NFNeal Flomenberg
Neal Flomenberg
Cytotoxic T lymphocytes (CTLs) destroy virally infected cells and are critical for the elimination of viral infections such as those caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Delayed and dysfunctional adaptive immune responses to SARS-CoV-2 are associated with poor outcomes. Treatment with allogeneic SARS-CoV-2–specific CTLs may enhance cellular immunity in high-risk patients providing a safe, direct mechanism of treatment. Thirty high-risk ambulatory patients with COVID-19 were enrolled in a phase 1 trial assessing the safety of third party, SARS-CoV-2–specific CTLs. Twelve interventional patients, 6 of whom were immunocompromised, matched the HLA-A∗02:01 restriction of the CTLs and received a single infusion of 1 of 4 escalating doses of a product containing 68.5% SARS-CoV-2–specific CD8+ CTLs/total cells. Symptom improvement and resolution in these patients was compared with an observational group of 18 patients lacking HLA-A∗02:01 who could receive standard of care. No dose-limiting toxicities were observed at any dosing level. Nasal swab polymerase chain reaction testing showed ≥88% and >99% viral elimination from baseline in all patients at 4 and 14 days after infusion, respectively. The CTLs did not interfere with the development of endogenous anti–SARS-CoV-2 humoral or cellular responses. T-cell receptor β analysis showed persistence of donor-derived SARS-CoV-2-specific CTLs through the end of the 6-month follow-up period. Interventional patients consistently reported symptomatic improvement 2 to 3 days after infusion, whereas improvement was more variable in observational patients. SARS-CoV-2–specific CTLs are a potentially feasible cellular therapy for COVID-19 illness. This trial was registered at www.clinicaltrials.gov as #NCT04765449.

9 May 2017 in Journal of Clinical Apheresis
Verified
Journal Article
Closed access
PDF file
APAlexis Peedin
Alexis Peedin
YPYara A. Park
Yara A. Park
JRJay S. Raval
Jay S. Raval

30 June 2019 in Blood Research
Verified
Journal Article
Open access
PDF file
APAlexis Peedin
Alexis Peedin
IPIrina Perjar
Irina Perjar
MMMarshall A. Mazepa
Marshall A. Mazepa
MRMarian A. Rollins-Raval
Marian A. Rollins-Raval
YPYara A. Park
Yara A. Park
JRJay S. Raval
Jay S. Raval
Peedin AR, et al. Blood Res. 2019 Jun;54(2):125-130. https://doi.org/10.5045/br.2019.54.2.125